Advanced Search

 

Study ID Status Title Patient Level Data
109801 Completed Complementary testing to further evaluate the immunogenicity of a GSK Biologicals’ HPV vaccine (580299) in healthy female subjects aged over 26 years enrolled in study 104820. Study Listed on ClinicalStudyDataRequest.com
109810 Completed To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247). Study Listed on ClinicalStudyDataRequest.com
109817 Completed Evaluate the reactogenicity & immunogenicity of 1 or 2 booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in primed adults aged between 19 & 61 years Study Listed on ClinicalStudyDataRequest.com
109821 Completed Observer blind study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals influenza vaccine GSK576389A administered to adults over 65 years previously vaccinated with the same vaccine, compared to Fluarix™ Study Listed on ClinicalStudyDataRequest.com
109825 Completed Safety and immunogenicity of GSK Biologicals’ (pre-) pandemic influenza candidate vaccine (GSK1562902A) in children aged 6 to 35 months Study Listed on ClinicalStudyDataRequest.com
109835 Completed Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children Study Listed on ClinicalStudyDataRequest.com
109836 Completed A multicentre study to evaluate the safety and immunogenicity of GSK Biologicals’ HPV vaccine (GSK1674330A) in healthy female subjects aged 18–25 years. Study Listed on ClinicalStudyDataRequest.com
109861 Completed Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix Study Listed on ClinicalStudyDataRequest.com
109995 Completed A phase IIIb, open, randomised, multicentre, primary study in healthy children, to establish the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ MeMuRu-OKA vaccine (administered at 9 and 15 months of age) versus Priorix™ (9 months of age) and Priorix™ co-administered with Varilrix™ at 15 months of age (comparator) and also to evaluate the non-inferiority of Priorix™ (9 months of age) and MeMuRu-OKA vaccine (15 months of age) versus the comparator, all administered subcutaneously as two-dose primary vaccination course Study Listed on ClinicalStudyDataRequest.com
110028 Completed A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant Study Listed on ClinicalStudyDataRequest.com
110031 Completed Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children. Study Listed on ClinicalStudyDataRequest.com
110040 Completed A single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1070806 in healthy and obese subjects. Study Listed on ClinicalStudyDataRequest.com
110058 Completed Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. Study Listed on ClinicalStudyDataRequest.com
110058 Completed Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age. Study Listed on ClinicalStudyDataRequest.com
110071 Completed Immune response to a hepatitis B vaccine challenge dose in healthy subjects who received primary vaccination of GlaxoSmithKline Biologicals' hepatitis B vaccine, approximately 20 years ago. Study Listed on ClinicalStudyDataRequest.com
110073 Completed Study to evaluate the immune response of healthy subjects who received neonatal vaccination course with GSK Biologicals’ Engerix™-B vaccine, approximately 20 years ago. Study Listed on ClinicalStudyDataRequest.com
110106 Completed A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Study Listed on ClinicalStudyDataRequest.com
110127 Completed Safety and immunogenicity study of GSK Biologicals’ cell culture-based influenza virus vaccine 1388442A compared with US licensed TIV in healthy adults Study Listed on ClinicalStudyDataRequest.com
110142 Completed Non-inferiority of co-administration of GSK Biologicals’pneumococcal conjugate vaccine GSK1024850A with DTPa-IPV-Hib versus co-administration with DTPa-HBV-IPV/Hib. Study Listed on ClinicalStudyDataRequest.com
110159 Completed A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber in male subjects with seasonal allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
110163 Completed A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and safety using an Environmental challenge chamber in male subjects with seasonal allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
110168 Completed Evaluation of the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine 580299 when administered as a 3-dose schedule in healthy Japanese pre-adolescent and adolescent female subjects. Study Listed on ClinicalStudyDataRequest.com
110215 Completed Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months Study Listed on ClinicalStudyDataRequest.com
110215 Completed Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months Study Listed on ClinicalStudyDataRequest.com
110221 Completed A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in people aged 18 years or above Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.